Mogrify develops a proprietary platform to identify transcriptomic and epigenetic cell switches that enable direct in vivo transdifferentiation between source and target human cell types. The company deploys next-generation sequencing and a human gene regulatory network‑centric approach to design in vivo reprogramming therapies. Its pipeline targets degenerative diseases of the eye, ear and pancreas, aiming to address vision loss, hearing loss and diabetes. Mogrify is advancing multiple programs through pre-clinical translation while optimizing its platform and working with biopharma collaborators. The company intends to use recent funding to progress a lead program into first‑in‑human studies and to deliver milestones needed for a Series B in 2024/25. Mogrify is headquartered in Cambridge, England. Mogrify, based in Cambridge, England, focuses on transforming ex vivo cell therapy development and pioneering in vivo reprogramming therapies. Its proprietary MOGRIFY and epiMOGRIFY platforms systematically identify transcriptomic and epigenetic cell switches to drive efficient and stable cellular reprogramming. The company is advancing immuno-oncology and ophthalmology programs, including iPSC-derived allogeneic cell therapies targeting hematological and solid malignancies and in vivo approaches aimed at retinal degeneration. Mogrify completed a Series A with a second close of $17 million, bringing total Series A proceeds to $33 million; funds will support platform development and IND-enabling studies. Proceeds are intended to advance lead assets toward the clinic and to address scalability and manufacturing in ex vivo therapies. The company also announced appointments to its board and observer roles tied to its progression. Mogrify applies a big-data, gene-regulatory network approach to identify conversion factors for producing clinically suitable cell types via direct cellular conversion. Its platform has been used to identify transcription factors and culture conditions needed to convert various cell types into mature chondrocytes. The company is developing both in vitro scalable production of chondrocytes for autologous and allogeneic implantation and an in vivo reprogramming therapy aimed at reversing osteoarthritis pathophysiology. Mogrify recently received additional Phase II funding to progress its regenerative cartilage therapy through preclinical safety and efficacy studies in vivo. The work is being advanced in collaboration with Dr. Wael Kafienah’s laboratory at the University of Bristol, and the company says it is now planning for clinical stages of development. The announcement cites Cambridge, England as the company’s location. Mogrify has developed a proprietary direct cellular conversion technology that transforms mature human cells into other cell types without passing through pluripotent or progenitor states. The company is deploying this platform to develop novel cell therapies addressing musculoskeletal, autoimmune, cancer immunotherapy, ocular and respiratory diseases and to build a broad IP position around scalable, safe and efficacious cell conversions. Mogrify commercializes the platform through development and out‑licence of internally developed cell therapy assets, licensing of novel cell conversion IP, and formation of joint ventures for non‑core areas. The company launched in February 2019 after a $3.7M seed round and has secured grants from Innovate UK and SBRI Healthcare. It recently closed an additional $16M funding round, bringing total capital raised to over $20M, with proceeds earmarked for internal cell therapy programmes and development/out‑licence of novel IP. Mogrify is expanding its Cambridge Science Park facility headcount to about 60 staff, recruiting up to 40 commercial, operational and scientific roles to support an expanding internal pipeline and collaborator projects. Mogrify applies a decade of academic research and a big data–science approach using next-generation sequencing and gene-regulatory data to identify factors that convert one mature cell type into another without passing through a pluripotent or progenitor state. Its core product is a predictive platform and associated IP that identifies optimal combinations of transcription factors or small molecules to drive direct reprogramming. The company plans to commercialize its technology via IP licensing, product development, and both internal and partnered drug-development programs. Mogrify says the approach is intended to address efficacy, safety and scalability challenges in current cell therapy development and manufacturing. Management highlights large addressable markets including a projected $30 billion cell therapy market and specific end-user markets such as cardiac repair and cartilage regeneration. The leadership team includes co-founders Julian Gough, Jose Polo and Owen Rackham and is chaired by Professor Steve Jackson; Darrin M. Disley was appointed CEO as part of the announced seed close.

Total raised

$32M

Funding rounds

5

Latest round

Series A

Latest activity

Oct 2023